Penetration of drugs through the blood-cerebrospinal fluid/blood-brain barrier for treatment of central nervous system infections.
about
Antibiotic therapy for adults with neurosyphilisTargeting innate immunity for neurodegenerative disorders of the central nervous systemChloramphenicol Derivatives as Antibacterial and Anticancer Agents: Historic Problems and Current SolutionsMaraviroc: a review of its use in HIV infection and beyondHerpes Simplex Virus Type 1 and Other Pathogens are Key Causative Factors in Sporadic Alzheimer's DiseaseClinically Available Medicines Demonstrating Anti-Toxoplasma ActivityExtensive Central Nervous System Cryptococcal Disease Presenting as Immune Reconstitution Syndrome in a Patient with Advanced HIV: Report of a Case and Review of Management Dilemmas and StrategiesMultifunctional nanoparticles for brain tumor imaging and therapy.Pharmacology of DB844, an orally active aza analogue of pafuramidine, in a monkey model of second stage human African trypanosomiasisSevere human monocytic ehrlichiosis presenting with altered mental status and seizures.Linezolid manifests a rapid and dramatic therapeutic effect for patients with life-threatening tuberculous meningitis.Photochemical internalization-mediated nonviral gene transfection: polyamine core-shell nanoparticles as gene carrier.Designing Novel Nanoformulations Targeting Glutamate Transporter Excitatory Amino Acid Transporter 2: Implications in Treating Drug Addiction.Ventricular shunt infections: immunopathogenesis and clinical management.Pharmacokinetics of single-dose daptomycin in patients with suspected or confirmed neurological infections.Increasing chloramphenicol resistance in Streptococcus pneumoniae isolates from Papua New Guinean children with acute bacterial meningitis.Ganciclovir penetrates into the cerebrospinal fluid of an infant with congenital cytomegalovirus infection.Meningeal inflammation increases artemether concentrations in cerebrospinal fluid in Papua New Guinean children treated with intramuscular artemether.Effect of protein binding on unbound atazanavir and darunavir cerebrospinal fluid concentrations.First human case of fatal Halicephalobus gingivalis meningoencephalitis in AustraliaMonitoring therapeutic monoclonal antibodies in brain tumor.Computational predictions of the site of metabolism of cytochrome P450 2D6 substrates: comparative analysis, molecular docking, bioactivation and toxicological implications.Staphylococcus aureus infection of the optic nerveIntracranial abscess due to Mycobacterium avium complex in an immunocompetent host: a case reportTissue distribution of pretomanid in rat brain via mass spectrometry imaging.Analysis of cerebrospinal fluid protein concentrations of patients with cryptococcal meningitis treated with antifungal agents.Rifampin use in acute community-acquired meningitis in intensive care units: the French retrospective cohort ACAM-ICU study.Development and validation of a liquid chromatography-tandem mass spectrometry (LC-MS/MS) method for the quantification of tigecycline in rat brain tissues.Tuberculous meningitis: diagnosis and treatment overview.In vitro study of the variable effects of proton pump inhibitors on voriconazoleScreening, treatment, and follow-up of syphilis patients: Issues, concerns and efforts to improve current paradigms.Communicating systems in the body: how microbiota and microglia cooperate.Pharmacokinetic and Pharmacodynamic Principles of Anti-infective Dosing.The antiviral drug ganciclovir does not inhibit microglial proliferation and activationPharmacokinetics of colistin in cerebrospinal fluid after intraventricular administration of colistin methanesulfonateImaging characteristics of disseminated Geosmithia argillacea causing severe diskospondylitis and meningoencephalomyelitis in a dogDesign, Synthesis, and Identification of Silicon Incorporated Oxazolidinone Antibiotics with Improved Brain Exposure.Assessment of blood-brain barrier penetration of miltefosine used to treat a fatal case of granulomatous amebic encephalitis possibly caused by an unusual Balamuthia mandrillaris strainCytokine patterns in a prospective cohort of HIV-infected patients with cryptococcal meningitis following initiation of antifungal and antiretroviral therapyClinical features, Outcomes and Molecular Profiles of Drug Resistance in Tuberculous Meningitis in non-HIV Patients
P2860
Q24188209-0B969C93-6DFE-41DC-9204-97C20EB2C9D5Q26744219-CBA16786-4C6D-462B-BD7A-19D620550D25Q26748249-4A17AEE3-D07C-4EAA-A11B-EBDE92BEB529Q26778504-ED398212-DF91-4A13-90C4-B6C89C11C1FEQ26781578-F0D70E1B-1ECD-4C68-87C7-11A60C8D1934Q26782581-8AF98234-F0BD-4923-A1C6-E024BD652D75Q26852378-2EE9B9A1-DBB9-4753-8DFC-7D0CB6880F79Q26865418-96E021A9-0707-4807-8214-D50F627445E3Q28481509-94AD0B60-6EBB-4E66-87B5-19709CDA14D4Q33436124-43D20B8A-E3E0-47B5-9A79-0F0AB08C753FQ34299173-0F4B3908-F204-4243-ACEF-74EB41CEED69Q34389909-26455952-D7AD-4BB7-B8A4-64F6B4AFFD62Q34504098-7306A8F1-2E3C-4A69-9E3D-21E39ECB6B1DQ34619785-E36DAE5F-92C5-4FCF-8B32-FB209FE8AEAAQ35065838-9FB70911-E6CD-4214-AD27-3C6A189FDBACQ35191559-B83D513A-28E2-4B4A-B198-C55A351D9C2AQ35315818-E911093D-1362-42FE-B0D7-193761EE23A6Q35363936-CDF93A34-DC4D-4E49-810E-BE2FFB41419BQ35404442-0B603705-3813-40A9-952A-0B85C3128A9EQ35455688-E3832950-CE58-440D-831C-652EF776AC0FQ35498835-7C122583-78F8-4B8A-897C-A4187C3D086EQ35646205-9BD8B5E8-0A5B-426B-B481-05974266CFB2Q35684455-DD79E2CD-1341-4393-96A8-EFB7C36A0E0BQ35706161-44404A1D-7FA4-4886-944D-C407F8D4EAB4Q35710470-7A9411FB-28AD-4CCD-B997-ED91FF7725B6Q35744569-ED3C820A-17DB-4AB6-AF53-337B6AB3326FQ35755083-30951623-1822-46EA-A724-1483629D13B4Q35778366-EB9B0C7D-5B72-4C8B-B2C3-01F47398A9B3Q35910242-E203835E-5D86-4209-9563-D4052060CB84Q35960842-F728A2E0-C39B-4709-A1B3-8A72BC76FED3Q36014802-78E09472-C6B8-4DD6-B724-1B7BF6C46CA0Q36071876-D10DB6D8-4651-4771-B4AD-84EF7114A287Q36083619-2CF47FB1-556A-4379-BF72-29AFE8920A5EQ36134639-11520013-D4BB-4E71-B5DF-F6F9FF2D3E4FQ36171581-EEF151C4-80D7-489B-91C8-7D168B73F5F8Q36270787-926117C7-BEF0-4B39-AB9B-876565FB1B17Q36281035-AF757951-23EC-43DE-80E2-98B783354FE8Q36365363-7145AF60-84E9-4C87-B4D8-7D408EFC7230Q36366992-CE060B92-5C86-470F-9D11-FC5EEB60E3ECQ36438322-B8367E6C-7799-481B-A23E-7974C48C4ED7
P2860
Penetration of drugs through the blood-cerebrospinal fluid/blood-brain barrier for treatment of central nervous system infections.
description
2010 nî lūn-bûn
@nan
2010 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Penetration of drugs through t ...... ral nervous system infections.
@ast
Penetration of drugs through t ...... ral nervous system infections.
@en
Penetration of drugs through t ...... ral nervous system infections.
@nl
type
label
Penetration of drugs through t ...... ral nervous system infections.
@ast
Penetration of drugs through t ...... ral nervous system infections.
@en
Penetration of drugs through t ...... ral nervous system infections.
@nl
prefLabel
Penetration of drugs through t ...... ral nervous system infections.
@ast
Penetration of drugs through t ...... ral nervous system infections.
@en
Penetration of drugs through t ...... ral nervous system infections.
@nl
P2093
P2860
P356
P1476
Penetration of drugs through t ...... ral nervous system infections.
@en
P2093
Fritz Sörgel
Helmut Eiffert
Roland Nau
P2860
P304
P356
10.1128/CMR.00007-10
P407
P577
2010-10-01T00:00:00Z